{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:37:49Z","timestamp":1777451869310,"version":"3.51.4"},"reference-count":21,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study assessed the effect of stavudine (d4T) 30 mg dosage on lipoatrophy in HIV-infected patients on antiretroviral treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A total of 243 patients from Cameroon receiving d4T or zidovudine (AZT) in combination with lamivudine and efavirenz or nevirapine for &gt;6 months were clinically assessed for moderate to severe (\u2018strict\u2019 definition) and mild to severe (\u2018large\u2019 definition) lipoatrophy. Prevalence of lipoatrophy was compared between 69 patients who had received exclusively d4T 30 mg (d4T\n                      <jats:sub>30<\/jats:sub>\n                      ), 64 patients who had received both d4T 30 and 40 mg dosages since treatment initiation (d4T\n                      <jats:sub>30\/40<\/jats:sub>\n                      ) and 110 patients on AZT-related therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Prevalence of lipoatrophy varied from 7% to 24%, according to the definition. After adjustment for gender, age, treatment duration and CD4\n                      <jats:sup>+<\/jats:sup>\n                      T-cell count, the risk of lipoatrophy in the d4T\n                      <jats:sub>30<\/jats:sub>\n                      group was lower than in the d4T\n                      <jats:sub>30\/40<\/jats:sub>\n                      group (odds ratio [OR] 0.3, 95% confidence interval [CI] 0.1\u20130.8 with the large definition and OR 0.2, 95% CI 0.0\u20130.8 with the strict definition) and was comparable to that of the AZT group (OR 1.0, 95% CI 0.2\u20134.6 and OR 1.0, 95% CI 0.4\u20132.2 with the large and strict definitions, respectively). The risk was significantly higher in the d4T\n                      <jats:sub>30\/40<\/jats:sub>\n                      group compared with the AZT group (OR 2.9, 95% CI 1.3\u20136.4 with the large definition and OR 5.5, 95% CI 1.3\u201323.5 with the strict definition).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The use of d4T at a lower dosage might increase safety with regard to its effect on lipoatrophy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3851\/imp1664","type":"journal-article","created":{"date-parts":[[2010,10,27]],"date-time":"2010-10-27T10:39:53Z","timestamp":1288175993000},"page":"1039-1043","source":"Crossref","is-referenced-by-count":12,"title":["Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon"],"prefix":"10.1177","volume":"15","author":[{"given":"Amandine","family":"Cournil","sequence":"first","affiliation":[{"name":"Institut de Recherche pour le D\u00e9veloppement, University Montpellier 1, UMR 145, Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathilde","family":"Coudray","sequence":"additional","affiliation":[{"name":"Institut de Recherche pour le D\u00e9veloppement, University Montpellier 1, UMR 145, Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Kouanfack","sequence":"additional","affiliation":[{"name":"Central Hospital, Yaound\u00e9, Cameroon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudine Ntsama","family":"Essomba","sequence":"additional","affiliation":[{"name":"Central Hospital, Yaound\u00e9, Cameroon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9ment Auguste Djouatsa","family":"Tonfack","sequence":"additional","affiliation":[{"name":"Central Hospital, Yaound\u00e9, Cameroon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magloire","family":"Biwol\u00e9-Sida","sequence":"additional","affiliation":[{"name":"Ministry of Public Health, Yaound\u00e9, Cameroon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Delaporte","sequence":"additional","affiliation":[{"name":"Institut de Recherche pour le D\u00e9veloppement, University Montpellier 1, UMR 145, Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten","family":"Bork","sequence":"additional","affiliation":[{"name":"Institut de Recherche pour le D\u00e9veloppement, University Montpellier 1, UMR 145, Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Laurent","sequence":"additional","affiliation":[{"name":"Institut de Recherche pour le D\u00e9veloppement, University Montpellier 1, UMR 145, Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2010,10,1]]},"reference":[{"key":"bibr1-IMP1664","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16586-0"},{"key":"bibr2-IMP1664","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.7.3.283"},{"key":"bibr3-IMP1664","unstructured":"World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Geneva: World Health Organization 2006. (Updated 3 February 2009. Accessed 26 November 2009.) Available from http:\/\/www.who.int\/hiv\/pub\/guidelines\/artadultguidelines.pdf."},{"key":"bibr4-IMP1664","unstructured":"World Health Organization. Important: addendum to the 2006 WHO guidelines on antiretroviral therapy for HIV infection in adults and adolescents: new dosage recommendations for stavudine (d4T). Geneva: World Health Organization 2007. (Updated 4 May 2007. Accessed 26 November 2009.) Available from http:\/\/www.who.int\/hiv\/art\/ARTadultsaddendum.pdf."},{"key":"bibr5-IMP1664","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2008.00616.x"},{"key":"bibr6-IMP1664","doi-asserted-by":"publisher","DOI":"10.1086\/529384"},{"key":"bibr7-IMP1664","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/135965350701200301","volume":"12","author":"Milinkovic A.","year":"2007","journal-title":"Antivir Ther"},{"key":"bibr8-IMP1664","doi-asserted-by":"publisher","DOI":"10.1310\/ED57-EU48-RK6A-E5U0"},{"key":"bibr9-IMP1664","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32832d3c5e"},{"key":"bibr10-IMP1664","unstructured":"World Health Organization. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. Geneva: World Health Organization 2009. (Updated 23 February 2010. Accessed 11 March 2010.) Available from http:\/\/www.who.int\/hiv\/pub\/arv\/rapid_advice_art.pdf."},{"key":"bibr11-IMP1664","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12656-6"},{"key":"bibr12-IMP1664","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31819c16f4"},{"key":"bibr13-IMP1664","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318158c0a6"},{"key":"bibr14-IMP1664","doi-asserted-by":"publisher","DOI":"10.1016\/j.trstmh.2007.02.020"},{"key":"bibr15-IMP1664","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1177\/135965350901400307","volume":"14","author":"Zannou D.M.","year":"2009","journal-title":"Antivir Ther"},{"key":"bibr16-IMP1664","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.2.207"},{"key":"bibr17-IMP1664","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200501030-00002"},{"key":"bibr18-IMP1664","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200305010-00004"},{"key":"bibr19-IMP1664","doi-asserted-by":"publisher","DOI":"10.1016\/j.trstmh.2008.08.015"},{"key":"bibr20-IMP1664","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200209010-00007"},{"key":"bibr21-IMP1664","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04056-3"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP1664","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP1664","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:49:39Z","timestamp":1777380579000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3851\/IMP1664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.3851\/IMP1664"],"URL":"https:\/\/doi.org\/10.3851\/imp1664","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}